QQ客服 官方微博 反馈留言

	Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China
	Wei, Lai; Xie, Qing; Hou, Jin Lin; Jia, Jidong; Li, Wu; Xu, Min; Li, Jun; Wu, Shanming; Cheng, Jun; Jiang, Jianning
刊名	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
	2018
卷号	33期号:6页码:1168-1176
关键词	direct-acting antiviral agents NS5B polymerase inhibitor pangenotypic SVR12
DOI	10.1111/jgh.14102
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4583638
专题	山东大学
作者单位	1.Peking Univ, Peoples Hosp, 11 Xizhimen S St, Beijing 100044, Peoples R China. 2.Capital Med Univ, Beijing Friendship Hosp, B
推荐引用方式 GB/T 7714	Wei, Lai,Xie, Qing,Hou, Jin Lin,et al. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2018,33(6):1168-1176.
APA	Wei, Lai.,Xie, Qing.,Hou, Jin Lin.,Jia, Jidong.,Li, Wu.,...&Wang, Guiqian 更多.(2018).Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,33(6),1168-1176.
MLA	Wei, Lai,et al."Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China".JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 33.6(2018):1168-1176.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。